Last reviewed 2026-05-16 · How we verify

qIRV (22/23) (qirv-22-23)

Pfizer · FDA-approved active Quality 50/100

qIRV (22/23) (generic name: qirv-22-23) is a Unknown drug developed by Pfizer. It is currently FDA-approved for COVID-19 prevention, COVID-19 treatment.

Pfizer's qIRV (22/23) is a marketed drug for COVID-19 prevention and treatment. It is a product of Pfizer Inc. The mechanism of qIRV is not specified. qIRV has key indications in COVID-19 prevention and treatment. There is no clinical differentiation available. qIRV has significant commercial value with $63.6B in revenue. There are no pipeline developments available.

At a glance

Generic name	qirv-22-23
Sponsor	Pfizer
Drug class	Unknown
Target	Unknown
Therapeutic area	Infectious Disease
Phase	FDA-approved

Approved indications

COVID-19 prevention
COVID-19 treatment

Common side effects

No common side effects on file.

Drug interactions

Atazanavir
Buprenorphine
Cobicistat
Darunavir
Dolutegravir
Efavirenz
Elvitegravir
Etravirine
Fosamprenavir
Indinavir
Lopinavir
Nelfinavir

Key clinical trials

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

qIRV (22/23) CI brief — competitive landscape report
qIRV (22/23) updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about qIRV (22/23)

What is qIRV (22/23)?

qIRV (22/23) (qirv-22-23) is a Unknown drug developed by Pfizer, indicated for COVID-19 prevention, COVID-19 treatment.

What is qIRV (22/23) used for?

qIRV (22/23) is indicated for COVID-19 prevention, COVID-19 treatment.

Who makes qIRV (22/23)?

qIRV (22/23) is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of qIRV (22/23)?

qirv-22-23 is the generic (nonproprietary) name of qIRV (22/23).

What drug class is qIRV (22/23) in?

qIRV (22/23) belongs to the Unknown class. See all Unknown drugs at /class/unknown.

What development phase is qIRV (22/23) in?

qIRV (22/23) is FDA-approved (marketed).

What does qIRV (22/23) target?

qIRV (22/23) targets Unknown and is a Unknown.

Drug class: All Unknown drugs
Target: All drugs targeting Unknown
Manufacturer: Pfizer — full pipeline
Therapeutic area: All drugs in Infectious Disease
Indication: Drugs for COVID-19 prevention
Indication: Drugs for COVID-19 treatment

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing